BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35245886)

  • 21. Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.
    Wu YC; Huang CS; Hsieh MS; Huang CM; Setiawan SA; Yeh CT; Kuo KT; Liu SC
    Aging (Albany NY); 2024 Jan; 16(1):627-647. PubMed ID: 38206305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
    Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
    Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
    Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
    Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
    Zhou W; Chen YW; Liu X; Chu P; Loria S; Wang Y; Yen Y; Chou KM
    PLoS One; 2013; 8(12):e83978. PubMed ID: 24376779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p38 Mitogen-activated protein kinase modulates cisplatin resistance in Head and Neck Squamous Cell Carcinoma cells.
    Roy S; Roy S; Anuja K; Thakur S; Akhter Y; Padhi S; Banerjee B
    Arch Oral Biol; 2021 Feb; 122():104981. PubMed ID: 33302041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel CREB5/TOP1MT axis confers cisplatin resistance through inhibiting mitochondrial apoptosis in head and neck squamous cell carcinoma.
    Tong T; Qin X; Jiang Y; Guo H; Wang X; Li Y; Xie F; Lu H; Zhai P; Ma H; Zhang J
    BMC Med; 2022 Jul; 20(1):231. PubMed ID: 35773668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of p38 MAPK in disease relapse and therapeutic resistance by maintenance of cancer stem cells in head and neck squamous cell carcinoma.
    Roy S; Roy S; Kar M; Padhi S; Saha A; Anuja K; Banerjee B
    J Oral Pathol Med; 2018 May; 47(5):492-501. PubMed ID: 29575240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD10 as a novel marker of therapeutic resistance and cancer stem cells in head and neck squamous cell carcinoma.
    Fukusumi T; Ishii H; Konno M; Yasui T; Nakahara S; Takenaka Y; Yamamoto Y; Nishikawa S; Kano Y; Ogawa H; Hasegawa S; Hamabe A; Haraguchi N; Doki Y; Mori M; Inohara H
    Br J Cancer; 2014 Jul; 111(3):506-14. PubMed ID: 24874475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical decision pathway and management of locally advanced head and neck squamous cell carcinoma: A multidisciplinary consensus in Asia-Pacific.
    Guo Y; Nakashima T; Cho BC; Lim DW; Yang MH; Lou PJ; Corry J; Lin JC; Zhu GP; Kim KH; Zhang B; Li Z; Hong RL; Ng JYS; Tan EM; Liu YP; Stylianou C; Spiteri C; Porceddu S
    Oral Oncol; 2024 Jan; 148():106657. PubMed ID: 38101313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
    Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
    Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
    Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
    Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
    Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
    Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
    Bourguignon LY; Wong G; Earle C; Chen L
    J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers of radioresistance in head and neck squamous cell carcinomas.
    Avril D; Foy JP; Bouaoud J; Grégoire V; Saintigny P
    Int J Radiat Biol; 2023; 99(4):583-593. PubMed ID: 35930497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
    Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.